Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation

Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States

9 p | 9 | 5

Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: Results from the randomized phase III ALCYONE trial

14 p | 11 | 2

Physical function in patients newly diagnosed with multiple myeloma; a Danish cohort study

11 p | 8 | 1

Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma

10 p | 6 | 1